Inhibikase Therapeutics Inc (IKT) - Net Assets
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has net assets worth $72.90 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($79.59 Million) and total liabilities ($6.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Inhibikase Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $72.90 Million |
| % of Total Assets | 91.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | 869.57% |
| 10-Year Change | N/A |
| Growth Volatility | 332.3 |
Inhibikase Therapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Inhibikase Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual net assets of Inhibikase Therapeutics Inc from 2016 to 2024. For live valuation and market cap data, see IKT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $94.87 Million | +764.16% |
| 2023-12-31 | $10.98 Million | -47.81% |
| 2022-12-31 | $21.04 Million | -45.24% |
| 2021-12-31 | $38.42 Million | +292.62% |
| 2020-12-31 | $9.78 Million | +317.91% |
| 2019-12-31 | $-4.49 Million | -477.15% |
| 2018-12-31 | $-777.97K | +46.01% |
| 2017-12-31 | $-1.44 Million | -6.61% |
| 2016-12-31 | $-1.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inhibikase Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9054839100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $69.36K | 0.07% |
| Other Comprehensive Income | $-37.25K | -0.04% |
| Other Components | $189.25 Million | 199.50% |
| Total Equity | $94.87 Million | 100.00% |
Inhibikase Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prime Office A/S
CO:PRIMOF
|
$119.31 Million |
|
Newcore Gold Ltd
V:NCAU
|
$119.32 Million |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
$119.34 Million |
|
Tonlin Department Store Co Ltd
TW:2910
|
$119.36 Million |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
$119.20 Million |
|
Tomer Energy Royalties (2012) Ltd
TA:DLRL
|
$119.20 Million |
|
OMER S.P.A. O.N.
F:9WR
|
$119.18 Million |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
$119.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inhibikase Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,977,922 to 94,866,280, a change of 83,888,358 (764.2%).
- Net loss of 27,519,886 reduced equity.
- New share issuances of 103,477,668 increased equity.
- Other comprehensive income decreased equity by 38,125.
- Other factors increased equity by 7,968,701.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.52 Million | -29.01% |
| Share Issuances | $103.48 Million | +109.08% |
| Other Comprehensive Income | $-38.12K | -0.04% |
| Other Changes | $7.97 Million | +8.4% |
| Total Change | $- | 764.16% |
Book Value vs Market Value Analysis
This analysis compares Inhibikase Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.04 | $1.91 | x |
| 2017-12-31 | $-0.84 | $1.91 | x |
| 2018-12-31 | $-0.58 | $1.91 | x |
| 2019-12-31 | $-2.61 | $1.91 | x |
| 2020-12-31 | $5.84 | $1.91 | x |
| 2021-12-31 | $12.66 | $1.91 | x |
| 2022-12-31 | $5.01 | $1.91 | x |
| 2023-12-31 | $2.06 | $1.91 | x |
| 2024-12-31 | $1.37 | $1.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inhibikase Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-29.01%) is above the historical average (-39.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -64.99% | 5.94x | 0.00x | $-493.57K |
| 2017 | 0.00% | -21.16% | 7.23x | 0.00x | $-291.97K |
| 2018 | 0.00% | -53.27% | 1.42x | 0.00x | $-2.07 Million |
| 2019 | 0.00% | -511.95% | 29.35x | 0.00x | $-5.30 Million |
| 2020 | -29.41% | -411.94% | 0.05x | 1.51x | $-3.86 Million |
| 2021 | -38.54% | -477.52% | 0.07x | 1.11x | $-18.65 Million |
| 2022 | -85.12% | -14505.22% | 0.00x | 1.19x | $-20.01 Million |
| 2023 | -173.34% | -7304.75% | 0.02x | 1.32x | $-20.13 Million |
| 2024 | -29.01% | 0.00% | 0.00x | 1.04x | $-37.01 Million |
Industry Comparison
This section compares Inhibikase Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inhibikase Therapeutics Inc (IKT) | $72.90 Million | 0.00% | 0.09x | $119.23 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more